Carlos Peula, Margalida Esteva-Socias, Kanchan Kumari, Erik Dassi, Francesca Aguilo
{"title":"通过SCAN-B队列分析乳腺癌mRNA修饰机制的改变。","authors":"Carlos Peula, Margalida Esteva-Socias, Kanchan Kumari, Erik Dassi, Francesca Aguilo","doi":"10.1093/narcan/zcaf027","DOIUrl":null,"url":null,"abstract":"<p><p>Epitranscriptomic modifications regulate gene expression and have been implicated in cancer, including breast cancer. Using the SCAN-B cohort, we analyzed 49 messenger RNA modification regulators (mRMPs) across breast cancer subtypes. In the basal subtype, we found significant overexpression of m<sup>6</sup>A readers (IGF2BP1-3), m<sup>5</sup>C regulators (NSUN5, ALYREF, YBX1, YBX2), pseudouridine [PUS1, MARS (or MetRS), RPUSD2], and RNA editing enzymes [APOBEC3A (A3A), A3G, ADAR1], all linked to poor survival. Conversely, the m<sup>6</sup>A writer METTL14 was downregulated. Our findings highlight key mRMPs as potential biomarkers and therapeutic targets, underscoring the role of RNA modifications in breast cancer progression.</p>","PeriodicalId":94149,"journal":{"name":"NAR cancer","volume":"7 3","pages":"zcaf027"},"PeriodicalIF":3.2000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409412/pdf/","citationCount":"0","resultStr":"{\"title\":\"Analysis of the mRNA modification machinery alterations in breast cancer through the SCAN-B cohort.\",\"authors\":\"Carlos Peula, Margalida Esteva-Socias, Kanchan Kumari, Erik Dassi, Francesca Aguilo\",\"doi\":\"10.1093/narcan/zcaf027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Epitranscriptomic modifications regulate gene expression and have been implicated in cancer, including breast cancer. Using the SCAN-B cohort, we analyzed 49 messenger RNA modification regulators (mRMPs) across breast cancer subtypes. In the basal subtype, we found significant overexpression of m<sup>6</sup>A readers (IGF2BP1-3), m<sup>5</sup>C regulators (NSUN5, ALYREF, YBX1, YBX2), pseudouridine [PUS1, MARS (or MetRS), RPUSD2], and RNA editing enzymes [APOBEC3A (A3A), A3G, ADAR1], all linked to poor survival. Conversely, the m<sup>6</sup>A writer METTL14 was downregulated. Our findings highlight key mRMPs as potential biomarkers and therapeutic targets, underscoring the role of RNA modifications in breast cancer progression.</p>\",\"PeriodicalId\":94149,\"journal\":{\"name\":\"NAR cancer\",\"volume\":\"7 3\",\"pages\":\"zcaf027\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409412/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NAR cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/narcan/zcaf027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NAR cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/narcan/zcaf027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Analysis of the mRNA modification machinery alterations in breast cancer through the SCAN-B cohort.
Epitranscriptomic modifications regulate gene expression and have been implicated in cancer, including breast cancer. Using the SCAN-B cohort, we analyzed 49 messenger RNA modification regulators (mRMPs) across breast cancer subtypes. In the basal subtype, we found significant overexpression of m6A readers (IGF2BP1-3), m5C regulators (NSUN5, ALYREF, YBX1, YBX2), pseudouridine [PUS1, MARS (or MetRS), RPUSD2], and RNA editing enzymes [APOBEC3A (A3A), A3G, ADAR1], all linked to poor survival. Conversely, the m6A writer METTL14 was downregulated. Our findings highlight key mRMPs as potential biomarkers and therapeutic targets, underscoring the role of RNA modifications in breast cancer progression.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
